Erudio Healtherudio.com
Clinical trial · no report yet · Phase 4
CAST-AI
Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
- NCT06764095 ↗
- Recruiting
- Mayo Clinic
- Focused
We haven't built an HCP commentary report on CAST-AI (enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CAST-AI so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- CAST-AI: Cystectomy After Systemic Therapy With ADC and Immunotherapy
- Phase
- Phase 4
- Status
- Recruiting
- Conditions
- Locally Advanced Bladder Urothelial Carcinoma; Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma; Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis and Ureter Urothelial Carcinoma; Stage III Bladder Cancer AJCC v8; Stage IV Bladder Cancer AJCC v8; Stage IV Renal Pelvis and Ureter Cancer AJCC v8
- Interventions
- Biospecimen Collection; Computed Tomography; Cystectomy; Enfortumab Vedotin; Local Therapy; Magnetic Resonance Imaging; Pembrolizumab; Positron Emission Tomography; Questionnaire Administration; Ureterectomy
- Arms
- Treatment (enfortumab vedotin, pembrolizumab) · Experimental
- Enrollment
- 75 (estimated)
- Primary outcomes
- Progression-free survival (PFS) at 12 months
- Sponsor
- Mayo Clinic
- Start
- Jan 8, 2025
- Primary completion
- Jul 1, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06764095 · updated Oct 1, 2026